| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
90,630,000 |
| Market
Cap: |
13.06(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$131.96 - $265 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 664 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BeiGene is a commercial-stage biotechnology company focused on developing and commercializing molecularly-targeted and immuno-oncology cancer therapeutics. Co.'s clinical-stage drug candidates include: Zanubrutinib, which is a small molecule inhibitor of Bruton's tyrosine kinase for the treatment of mantle cell lymphoma in adult patients; Tislelizumab, which is a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1; Pamiparib (BGB-290), which is for the treatment of various solid tumors; and Lifirafenib, which is an investigational small molecule inhibitor with RAF monomer and dimer inhibition activities.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
100,397 |
1,200,397 |
5,371,251 |
5,588,274 |
| Total Sell Value |
$15,909,372 |
$214,459,372 |
$1,041,558,017 |
$1,085,894,829 |
| Total People Sold |
2 |
3 |
8 |
9 |
| Total Sell Transactions |
6 |
7 |
21 |
54 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Huang Jane |
CMO, Hematology |
• – – |
2021-09-20 |
4 |
AS |
$390.91 |
$2,387,774 |
D/D |
(6,000) |
0 |
|
-39% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2021-09-20 |
4 |
OE |
$119.96 |
$719,760 |
D/D |
6,000 |
6,000 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • – |
2021-09-15 |
4 |
AS |
$374.39 |
$9,864,173 |
D/D |
(26,158) |
0 |
|
-40% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2021-09-15 |
4 |
AS |
$29.31 |
$5,575,287 |
D/D |
(190,203) |
1,736,904 |
|
-40% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2021-09-14 |
4 |
AS |
$361.56 |
$13,901,782 |
D/D |
(37,877) |
0 |
|
-37% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2021-09-14 |
4 |
AS |
$28.22 |
$4,447,078 |
D/D |
(157,600) |
2,267,161 |
|
-37% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2021-09-13 |
4 |
AS |
$355.37 |
$4,620,390 |
D/D |
(12,901) |
0 |
|
-32% |
|
| Amgen Inc |
10% Owner |
– – • |
2021-09-10 |
4 |
B |
$302.06 |
$49,999,938 |
D/D |
165,529 |
18,943,802 |
2.45 |
-29% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2021-09-02 |
4 |
S |
$327.18 |
$178,314 |
D/D |
(545) |
0 |
|
29% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2021-09-02 |
4 |
AS |
$324.50 |
$8,040,809 |
D/D |
(24,499) |
0 |
|
-29% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2021-09-01 |
4 |
A |
$0.00 |
$0 |
D/D |
545 |
545 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2021-09-01 |
4 |
S |
$310.53 |
$168,307 |
D/D |
(542) |
0 |
|
24% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2021-09-01 |
4 |
A |
$0.00 |
$0 |
D/D |
7,124 |
312,948 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • – |
2021-09-01 |
4 |
AS |
$324.41 |
$8,306,484 |
D/D |
(25,501) |
0 |
|
-24% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2021-09-01 |
4 |
AS |
$24.34 |
$3,105,165 |
D/D |
(127,558) |
2,917,162 |
|
-24% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2021-08-31 |
4 |
A |
$0.00 |
$0 |
D/D |
542 |
542 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2021-08-31 |
4 |
A |
$0.00 |
$0 |
D/D |
7,163 |
305,824 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • – |
2021-08-31 |
4 |
AS |
$299.74 |
$10,415,111 |
D/D |
(34,281) |
0 |
|
-22% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2021-08-31 |
4 |
AS |
$23.67 |
$1,817,756 |
D/D |
(76,800) |
3,694,720 |
|
-22% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2021-08-05 |
4 |
AS |
$331.64 |
$3,497,744 |
D/D |
(10,362) |
0 |
|
-17% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2021-08-05 |
4 |
AS |
$25.82 |
$880,302 |
D/D |
(34,100) |
4,217,173 |
|
-17% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2021-08-04 |
4 |
AS |
$340.40 |
$10,925,109 |
D/D |
(31,747) |
0 |
|
-18% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2021-08-04 |
4 |
AS |
$26.08 |
$1,280,479 |
D/D |
(49,100) |
4,385,979 |
|
-18% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2021-08-03 |
4 |
AS |
$323.74 |
$14,160,167 |
D/D |
(41,959) |
0 |
|
-13% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2021-08-03 |
4 |
AS |
$25.17 |
$1,041,881 |
D/D |
(41,400) |
4,847,790 |
|
-13% |
|
243 Records found
|
|
Page 1 of 10 |
|
|
5.13 (3.69%) 
